Sinovac Starts Review Process for Approval of COVID-19 Vaccine in Europe

Beijing Sinovac's   inactivated COVID-19 (Vero Cell) vaccine has started a rolling review in Europe . CoronaVac is the first China-developed COVID-19 vaccine under consideration in Europe, joining vaccines from CureVac, Novavax and a Russian vaccine, Sputnik V. Sinovac has conducted large-scale trials in Brazil and other countries, though the efficacy rates varied from 50% to 91%. The low number was from Brazil and may reflect the difficulty of fighting Brazil 's variant of the SARS-CoV-2 infection. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.